Biohaven rises on positive early-stage antibody drug trial results
U.S. STOCKS ON THE MOVE-Robinhood, Snowflake, Super Micro
U.S. STOCKS ON THE MOVE-AMC, Alnylam, Super Micro
Scholar Rock hits 3-year high on rival Biohaven's drug setback
U.S. STOCKS ON THE MOVE-Replimune, Snowflake, Virpax Pharmaceuticals
Biohaven falls as genetic disorder drug fails to meet goal in late-stage study
Biohaven's spinal muscular atrophy drug fails to meet main goal in study (updated)
Biohaven's spinal muscular atrophy drug fails to meet main goal in study
Brief: Biohaven Provides Update On Taldefgrobep Alfa Development Program
U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot
Scholar Rock surges as genetic disease drug succeeds in late-stage trial
U.S. RESEARCH ROUNDUP-Chargepoint Holdings, Harley-Davidson, Humana
U.S. STOCKS ON THE MOVE-Paychex, Dine Brands, Pinterest
U.S. STOCKS ON THE MOVE-Sagimet, Datadog, Clorox
U.S. STOCKS ON THE MOVE-Atlassian, Meta, Alphabet
Biohaven down after $250 mln stock offering prices
Biohaven down after unveiling $250 mln stock offering
Brief: Biohaven Announces Proposed Public Offering Of Common Shares
Brief: Biohaven Initiates Trial Of Drug For Treatment Of Migraine